Published in J Clin Invest on September 01, 1989
Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol (2010) 1.78
20-Hydroxyvitamin D2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells. Am J Physiol Cell Physiol (2010) 1.54
A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J Clin Invest (1993) 0.85
Are new vitamin D analogues in renal bone disease superior to calcitriol? Pediatr Nephrol (2005) 0.82
Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol (2005) 0.79
Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients. Clin Exp Nephrol (2005) 0.76
New Vitamin D analogues for osteodystrophy in chronic kidney disease. Pediatr Nephrol (2004) 0.76
The development of a bone- and parathyroid-specific analog of vitamin D: 2-methylene-19-Nor-(20S)-1α,25-dihydroxyvitamin D3. Bonekey Rep (2014) 0.76
High peripheral and axial bone densities in a postmenopausal woman with untreated hypoparathyroidism. Postgrad Med J (1990) 0.76
Preventing bone disease requires diligent management in patients with renal failure. West J Med (1994) 0.75
Effects of 1,25(OH)₂D₃ on Cancer Cells and Potential Applications in Combination with Established and Putative Anti-Cancer Agents. Nutrients (2017) 0.75
Adsorption of oxacalcitriol by polysulphone haemodialyser in patients with secondary hyperparathyroidism. Br J Clin Pharmacol (2004) 0.75
Molecular and morphological approach of uremia-induced hyperplastic parathyroid gland following direct maxacalcitol injection. Med Mol Morphol (2008) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest (1986) 2.07
Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest (1984) 1.88
Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci U S A (1985) 1.86
Metabolism in immunoreactive parathyroid hormone in the dog. The role of the kidney and the effects of chronic renal disease. J Clin Invest (1975) 1.70
Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol (1988) 1.40
Decrease in serum immunoreactive parathyroid hormone in rats and in parathyroid hormone secretion in vitro by 1,25-dihydroxycholecalciferol. J Clin Invest (1975) 1.33
Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene. Endocrinology (1986) 1.29
1,25-Dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture. Endocrinology (1985) 1.25
Preparation of viable isolated bovine parathyroid cells. Endocrinology (1976) 1.22
Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med (1986) 1.19
Studies on the mechanism of action of calciferol VII. Localization of 1,25-dihydroxy-vitamin D3 in chick parathyroid glands. Biochem Biophys Res Commun (1975) 1.14
Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab (1982) 1.13
Direct regulation by calcium of cytoplasmic messenger ribonucleic acid coding for pre-proparathyroid hormone in isolated bovine parathyroid cells. J Clin Invest (1983) 1.07
The effect of 1,25 dihydroxycholecalciferol on parathyroid hormone secretion by monolayer cultures of bovine parathyroid cells. Calcif Tissue Int (1986) 1.03
1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann Intern Med (1978) 1.02
Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest (1989) 1.01
The effects of calcium and magnesium on the secretion of parathormone and parathyroid secretory protein by isolated porcine parathyroid cells. Endocrinology (1978) 0.92
Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism. Proc Eur Dial Transplant Assoc (1983) 0.88
Use of calcium carbonate as a phosphate binder in dialysis patients. Miner Electrolyte Metab (1986) 0.84
Synthetic studies of vitamin D3 analogues. VIII. Synthesis of 22-oxavitamin D3 analogues. Chem Pharm Bull (Tokyo) (1986) 0.84
Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis. J Pediatr (1986) 0.81
"High-dose" calcitriol for control of renal osteodystrophy in children on CAPD. Kidney Int (1987) 0.80
Experience with 1,25-dihydroxycholecalciferol therapy in undergoing hemodialysis patients with progressive vitamin D2-treated osteodystrophy. Am J Med (1979) 0.80
24- and 26-homo-1,25-dihydroxyvitamin D3: preferential activity in inducing differentiation of human leukemia cells HL-60 in vitro. Proc Natl Acad Sci U S A (1987) 0.78
Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell (1998) 3.71
Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A (1991) 2.44
1 alpha,25-Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun (1981) 2.21
Studies on the characteristics of the control system governing sodium excretion in uremic man. J Clin Invest (1968) 2.16
Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int (2007) 2.15
Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis (1991) 2.13
agr expression precedes escape of internalized Staphylococcus aureus from the host endosome. Infect Immun (2001) 2.11
Vitamin D. Am J Physiol (1999) 2.10
A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis (1999) 2.07
Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother (1998) 2.04
Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N Engl J Med (1981) 2.00
Alternative DNA loops regulate the arabinose operon in Escherichia coli. Proc Natl Acad Sci U S A (1988) 1.95
Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest (1984) 1.88
25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int (2006) 1.84
The metabolic fate of vitamin D3-3H in chronic renal failure. J Clin Invest (1968) 1.79
Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women. Ann Intern Med (1988) 1.77
Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant (1999) 1.77
A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol (1999) 1.71
Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathic osteoporosis. Proc Natl Acad Sci U S A (1987) 1.70
Metabolism in immunoreactive parathyroid hormone in the dog. The role of the kidney and the effects of chronic renal disease. J Clin Invest (1975) 1.70
Caclium, phosphorus, and bone in renal disease and transplantation. Arch Intern Med (1969) 1.66
On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest (1971) 1.66
Evaluating organizational design to assure technology transfer: the case of the Community Clinical Oncology Program. J Natl Cancer Inst (1989) 1.65
1 alpha,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). Biochem J (1982) 1.63
p21(WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int (2001) 1.63
Germ-line mutational analysis of the TSC2 gene in 90 tuberous-sclerosis patients. Am J Hum Genet (1998) 1.61
Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol (2000) 1.61
1 alpha,25-Dihydroxyvitamin D3 and 1 alpha-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci U S A (1983) 1.60
Secretion and metabolic efficacy of parthyroid hormone in patients with severe hypomagnesemia. J Clin Endocrinol Metab (1974) 1.49
Regulation of the urea cycle and TCA cycle by ammonia. Adv Enzyme Regul (1966) 1.48
Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis (1997) 1.48
Glucose titration studies in patients with chronic progressive renal disease. J Clin Invest (1967) 1.43
Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int (1995) 1.42
Control of phosphate excretion in uremic man. J Clin Invest (1968) 1.41
ENL, the gene fused with HRX in t(11;19) leukemias, encodes a nuclear protein with transcriptional activation potential in lymphoid and myeloid cells. Blood (1994) 1.39
On the influence of extracellular fluid volume expansion and of uremia on bicarbonate reabsorption in man. J Clin Invest (1970) 1.38
Validation of the Quick Confusion Scale for mental status screening in the emergency department. Intern Emerg Med (2007) 1.38
Effect of administration of thyroxine on the risk of postpartum recurrence of hyperthyroid Graves' disease. J Clin Endocrinol Metab (1992) 1.38
Social support and health: a review. J Adv Nurs (1993) 1.37
The control of phosphate excretion in uremia. J Clin Invest (1966) 1.36
Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int (1993) 1.35
Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int J Cancer (2000) 1.35
On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kidney Int (1972) 1.34
Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol (1999) 1.34
Internet dominates providers' line of sight. Mod Healthc (2000) 1.29
Retinal changes in Himalayan climbers. Arch Ophthalmol (1975) 1.28
The peripheral metabolism of parathyroid hormone. N Engl J Med (1979) 1.26
1 alpha,25-dihydroxyvitamin D3 promotes fusion of mouse alveolar macrophages both by a direct mechanism and by a spleen cell-mediated indirect mechanism. Proc Natl Acad Sci U S A (1983) 1.24
Cleavage of parathyroid hormone in macrophage endosomes illustrates a novel pathway for intracellular processing of proteins. J Biol Chem (1989) 1.24
Purification of cytochrome P-450D1 alpha (25-hydroxyvitamin D3-1 alpha-hydroxylase) of bovine kidney mitochondria. Biochem Biophys Res Commun (1982) 1.23
Service system integration, access to services, and housing outcomes in a program for homeless persons with severe mental illness. Am J Public Health (1998) 1.22
Calcium and phosphate metabolism in tumoral calcinosis. Ann Intern Med (1980) 1.22
Glomerular filtration rate. Determination in patients with chronic renal disease. JAMA (1967) 1.22
Predicting the performance of a strategic alliance: an analysis of the Community Clinical Oncology Program. Health Serv Res (1993) 1.21
In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis. Antimicrob Agents Chemother (2000) 1.21
Service delivery and community: social capital, service systems integration, and outcomes among homeless persons with severe mental illness. Health Serv Res (2001) 1.21
The new kidney disease: improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification. Clin Nephrol (2010) 1.21
Selective uptake of intact parathyroid hormone by the liver: differences between hepatic and renal uptake. J Clin Invest (1976) 1.21
1Alpha,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone secretion. J Cell Biochem (1999) 1.21
Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis (1992) 1.20
Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int (1990) 1.20
Police perspectives on responding to mentally ill people in crisis: perceptions of program effectiveness. Behav Sci Law (1998) 1.20
Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med (1986) 1.19
Serial measurements of serum calcium, magnesium, parathyroid hormone, calcitonin, and 25-hydroxy-vitamin D in premature and term infants during the first week of life. Pediatr Res (1977) 1.19
Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis. Am J Physiol Renal Physiol (2001) 1.18
Additive effects of weight-bearing exercise and estrogen on bone mineral density in older women. J Bone Miner Res (1995) 1.17
Ultrastructure of capillary plaque-like degeneration in senile dementia. Mechanism of amyloid production. Acta Neuropathol (1974) 1.16
Effects of phosphate depletion and parathyroid hormone on renal glucose reabsorption. Am J Physiol (1974) 1.15
The regulation of sodium excretion in uremia: a new dimension in the characterization of "third factor". Trans Assoc Am Physicians (1966) 1.14
gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. J Clin Endocrinol Metab (1997) 1.13
Competitive protein-binding radioassay of 24,25-dihydroxyvitamin D in sera from normal and anephric subjects. Arch Biochem Biophys (1977) 1.13
The staphylococcal transferrin receptor: a glycolytic enzyme with novel functions. Trends Microbiol (2000) 1.12
Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob Agents Chemother (2001) 1.10
Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol (1996) 1.09
Evidence for an intrinsic renal tubular defect in mice with genetic hypophosphatemic rickets. J Clin Invest (1979) 1.08
Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kidney Int (1994) 1.07
Pharmacokinetics of cefotaxime in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis. J Antimicrob Chemother (1984) 1.07
The uptake and long-term storage of India ink particles and latex beads by fibroblasts in the dermis and subcutis of mice, with special regard to the non-inflammatory defense reaction by fibroblasts. Arch Histol Cytol (1988) 1.06
Parathormone levels after subtotal and total (autotransplantation) parathyroidectomy for secondary hyperparathyroidism. J Surg Res (1980) 1.06
Inhibitory effects of hypermagnesemia on the renal action of parathyroid hormone. J Clin Invest (1976) 1.05
The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int (1973) 1.05
Effects of hypervitaminosis A on the bone and mineral metabolism of the rat. Endocrinology (1988) 1.04
A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis (1995) 1.04
Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol (2001) 1.04
Inactivation of DNA mismatch repair by increased expression of yeast MLH1. Mol Cell Biol (2001) 1.03
Degradation of parathyroid hormone and fragment production by the isolated perfused dog kidney. The effect of glomerular filtration rate and perfusate CA++ concentrations. J Clin Invest (1977) 1.03
HPV-related cancers after solid organ transplantation in the United States. Am J Transplant (2013) 1.03
Prevention of immunological disorders in MRL/l mice by a new synthetic analogue of vitamin D3: 22-oxa-1 alpha,25-dihydroxyvitamin D3. J Nutr Sci Vitaminol (Tokyo) (1990) 1.03
The effect of 1,25 dihydroxycholecalciferol on parathyroid hormone secretion by monolayer cultures of bovine parathyroid cells. Calcif Tissue Int (1986) 1.03
Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest (1989) 1.01
Evidence for skeletal resistance to parathyroid hormone in magnesium deficiency. Studies in isolated perfused bone. J Clin Invest (1979) 1.01
Biodesulfurization of dibenzothiophene and its derivatives through the selective cleavage of carbon-sulfur bonds by a moderately thermophilic bacterium Bacillus subtilis WU-S2B. J Biosci Bioeng (2001) 1.01
The renal handling of parathyroid hormone. Role of peritubular uptake and glomerular filtration. J Clin Invest (1977) 1.00